Life
FDA Urges Drugmakers to Address Unreported Clinical Trial Results
An FDA analysis reveals that almost 30% of clinical trials, likely subject to mandatory reporting, have not submitted their results, prompting calls for accountability from drug manufacturers.
editorial-staff
1 min read
Updated about 12 hours ago
Summary
The FDA has highlighted a significant issue in clinical trial reporting, indicating that nearly 30% of studies that are likely required to report their results have failed to do so.
This finding comes from an internal analysis conducted by FDA officials, raising concerns about transparency and accountability in drug development.
The agency's push for compliance underscores the importance of ensuring that all clinical trial results are reported, as this information is crucial for public health and informed decision-making.
Updates
- No subsequent updates recorded.